TG Therapeutics, Inc. Announces Presentation of Phase 1 Data for Single-Agent Ublituximab (TG-1101) at the American Society of Clinical Oncology Meeting on June 2, 2013

Published: May 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, May 16, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced that Phase 1 Data for single-agent Ublituximab (TG-1101) will be presented at the American Society of Clinical Oncology Meeting on June 2, 2013. Abstract #8575 entitled "A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients", is available online at (http://abstracts2.asco.org/AbstView_132_117724.html).

Help employers find you! Check out all the jobs and post your resume.

Back to news